Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Janux Therapeutics

Janux Therapeutics (NASDAQ: JANX) insider transactions

In the twelve months to 10 November 2026, executives and directors of Janux Therapeutics reported 11 open-market sales of 31,796 shares ($557,052) and 0 open-market purchases, by 7 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Janux Therapeutics shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
31 July 2026Campbell David AlanPresident and CEOGift−123,840—264,742Form 4
8 July 2026Campbell David AlanPresident and CEOOption exercise+7,000$4.21388,582Form 4
11 June 2026Dobmeier EricDirectorGrant or award+5,500—15,481Form 4
11 June 2026RA Capital Nexus Fund II, L.P.DirectorGrant or award+5,500—11,750Form 4
11 June 2026Capps Vickie LDirectorGrant or award+5,500—79,598Form 4
11 June 2026Barrett Ronald WDirectorGrant or award+5,500—11,750Form 4
11 June 2026Kung WinstonDirectorGrant or award+5,500—11,750Form 4
11 June 2026Hernday NatashaDirectorGrant or award+5,500—15,481Form 4
11 June 2026Simson JakeDirectorGrant or award+5,500—11,750Form 4
2 June 2026Doyle Janeen NoelChief Corp. & Bus. Dev. OfcrOpen-market sale−4,059$14.0375,941Form 4
11 May 2026Dobek MariaVice President, AccountingOpen-market sale−2,038$14.1732,270Form 4
2 February 2026Go WilliamChief Medical OfficerGrant or award+44,000—44,000Form 4
2 January 2026Campbell David AlanPresident and CEOOpen-market sale−8,072$13.73284,982Form 4
2 January 2026Campbell David AlanPresident and CEOGrant or award+96,600—381,582Form 4
2 January 2026Meyer Andrew HollmanChief Business OfficerOpen-market sale−1,879$13.7383,095Form 4
2 January 2026Winter Charles M.Chief Technical OfficerOpen-market sale−2,401$13.7377,721Form 4
2 January 2026Winter Charles M.Chief Technical OfficerGrant or award+28,600—106,321Form 4
2 January 2026DiRaimondo ThomasChief Scientific OfficerOpen-market sale−2,505$13.73124,425Form 4
2 January 2026DiRaimondo ThomasChief Scientific OfficerGrant or award+31,400—155,825Form 4
2 January 2026Dobek MariaVice President, AccountingOpen-market sale−1,462$13.7315,373Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Janux Therapeutics page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.